Skip to main content

Inadequate reporting quality of registered genome editing trials: an observational study



To assess registration completeness and safety data of trials on human genome editing (HGE) reported in primary registries and published in journals, as HGE has safety and ethical problems, including the risk of undesirable and unpredictable outcomes. Registration transparency has not been evaluated for clinical trials using these novel and revolutionary techniques in human participants.


Observational study of trials involving engineered site-specific nucleases and long-term follow-up observations, identified from the WHO ICTRP HGE Registry in November 2020 and two comprehensive reviews published in the same year. Registration and adverse events (AEs) information were collected from public registries and matching publications. Published data were extracted in May 2021.


Among 81 eligible trials, most were recruiting (51.9%) phase 1 trials (45.7%). Five trials were withdrawn. Most trials investigated CAR T cells therapies (45.7%) and used CRISPR/Cas9 (35.8%) ex vivo (88.9%). Among 12 trials with protocols both registered and published, eligibility criteria, sample size, and secondary outcome measures were consistently reported for less than a half. Three trials posted results in, and one reported serious AEs.


Incomplete registration and published data give emphasis to the need to increase the transparency of HGE trials. Further improvements in registration requirements, including phase 1 trials, and a more controlled publication procedure, are needed to augment the implementation of this promising technology.

Peer Review reports


Human gene therapy (GT) products are biological products that have a potential to fulfill unmet medical needs [1] but are also challenging to regulators because of highly complex information on their development and manufacture [1,2,3,4]. According to the FDA consideration, “human gene therapy products” are defined as „all products that mediate their effects by transcription or translation of transferred genetic material, or by specifically altering host (human) genetic sequences “ [3]. The development of innovative approaches, including programmable nucleases [5,6,7], led to the explosion of interest for use of genome editing [8], and a move beyond the basic laboratory research to early clinical uses [5, 8,9,10,11,12,13]. The term “genome editing” refers “to the processes by which the genome sequence is changed by adding, replacing, or removing DNA base pairs” [3, 8].

Despite their potential for different diseases [14, 15], there are still emerging issues surrounding the safety and effectiveness of GT, including early failures [1], outcomes such as death [16], late-onset T-cell leukemia [17], and brain and spinal cord tumors [18]. Due to possible non-specific off-target genome changes, insertional mutagenesis with integrating vectors, or immune response to product components, participants in trials with genome editing-based GT products may experience unpredictable and delayed adverse events (AEs) [8, 19]. To better interpret that risk, monitoring of long-term safety is recommended [19, 20]. Although AEs are mandated to be reported for all interventional trials except phase 1 involving FDA-regulated drug, biological, or device products [21, 22], reporting transparency is still low [23,24,25].

The aim of our study was to assess the registration completeness and published data in journal articles for trials testing genome editing therapies.


Sample and inclusion criteria

On November 12, 2020, we retrieved clinical trials using genome editing technologies from the Human Genome Editing (HGE) Registry provided by the WHO International Clinical Trials Registry Platform (ICTRP) [26], without any set limitations. We also checked two comprehensive tables published in 2020 [5, 9] on trials that involved genome editing. A clinical trial was considered a “HGE trial” if it: 1) had a registry identification number and available registration protocol, 2) was registered on or before November 12, 2020, and 3) involved in vivo or ex vivo interventions using engineered site-specific nucleases to alter human cells for purposes of treating or preventing disease, or was 4) long-term follow-up (LTFU) observation with extended assessments. Basic laboratory studies on human cells or tissues focusing on cellular, molecular, biochemical, genetic, or immunological mechanisms, and duplicate trials registered in two or more registries, were excluded from the analysis.

Publication search

Corresponding publications were identified in May 2021 by screening the following sources: 1) the Publications subheading under the Descriptive Information heading, 2) PubMed/MEDLINE, and 3) Scopus. The manual search used 1) trial unique identification number, and 2) combination of search terms for each trial: intervention name, nuclease platform used, edited gene/cells, condition, study phase, and all names under “investigators” field in different public registries.

WHO ICTRP data extraction

We extracted data on 21 out of 24 items from the WHO Trial Registration Data Set (TRDS) [27] until February 2021. Administrative items (3, 7 and 8) were not extracted. We also extracted data describing HGE technology (edited cells, target gene, nuclease platform used, and modes of delivery).

For trials with posted results, we calculated the median time for results reporting from the primary completion date (PCD) [22]. In May 2021, we re-evaluated whether trials posted results in the registry.

Data analysis

Registration and publication data were extracted independently by two reviewers (M.Z., D.J.), after all three investigators (M.Z., D.J., A.M.) established the final extraction protocol through the pilot extraction of a 10% random sample. The data are presented as frequencies and medians with 95% confidence intervals. MedCalc version 20.008 (MedCalc Software, Ostend, Belgium) was used.


General characteristics of registered HGE trials

From 122 identified trials (Fig. 1), we excluded 41 (33.6%) because of in vitro trial design, incorrect identification, clustered regularly interspaced short palindromic repeats (CRISPR)-based diagnosis as trial purpose, and registration of the same trial in two registries. Of the remaining 81 trials, most were interventional (96.3%), with single group assignment as the most common model (60.3%, Table 1). The majority of trials with administered interventions were without blinding (78.2%), a half were in phase 1 (47.4%), and 25 interventional trials (32.1%) reported the use of a FDA-regulated drug product under their study intervention. The use of the randomization method was reported in 6 trials that had parallel design, but detailed information regarding the randomization process, mostly challenging to these trials, were missing.

Fig. 1
figure 1

Flow-chart of the search and selection of eligible clinical trials using genome editing technologies. *For this observational study “human GT products” were defined according to the FDA as „all products that meet the definition of biological products and that mediate their effects by transcription or translation of transferred genetic material, or by specifically altering host (human) genetic sequences “ [3]. The term “human genome editing” is used “to refer to the processes by which the genome sequence is changed by adding, replacing, or removing DNA base pairs” [3, 8]. †Of the remaining 81 trials, 21 (25.9%) were identified only in WHO ICTRP, 47 (58.0%) also in published review(s), and 13 (16.0%) in only published review(s). Considering primary registries in the WHO registry network, 62 trials (76.5%) were registered only in, 6 (7.4%) both in and EU Clinical Trials Register (EU-CTR) (2 trials had equal protocol registered for 2 EU member states), 1 (1.2%) only in EU-CTR, and 12 (14.8%) trials only in Chinese Clinical Trial Registry (ChiCTR)

Table 1 Design of 81 trials on genome editing in humans registered in WHO ICTRP

In 3 trials that clearly noted the use of a sham control, patient’s lymphocytes were collected and infused back to the patients without any genetic or engineered modification ex vivo.

Three trials were registered as LTFU trials, referring to subjects treated with CCR5-zinc-finger nuclease (ZFN) modified autologous T cells, CRISPR/CRISPR-associated protein (Cas) 9 modified autologous hematopoietic stem cells, and UCART19, respectively.

Most trials included participants of both genders (91.4%, Supplementary Table 1), aged 18–70. Among 7 trials that investigated HGE technology in a single gender, 1 explicitly provided a “gender eligibility description” (NCT03525652).

Among 52 trials that had any registration entry for individual participant data (IPD) sharing statement, 22 trials (42.3%) will not share de-identified IPD. Regarding the data monitoring committee, 28 trials (34.6%) stated “no”, 43 (53.1%) stated “yes”, and 10 (12.3%) did not provide any information.

More than half of the trials had a “recruiting” status (51.9%) and were prospectively registered (67.9%, Supplementary Table 2). For almost a third of trials, the information on investigators were absent (30.9%). Most HGE trials were sponsored by industry (44.4%) and conducted in China (48.1%). Among 33 trials whose study completion date (SCD) was until May 2021 (median 2019, 95% CI 2018–2020, range 2013–2021), 3 trials (9.1%) had a “not yet recruiting” status, whilst 7 (21.2%) were still recruiting.

In 2017 or 2018, 4 trials changed their status to “unknown” from “not yet recruiting”, “recruiting”, or “active, not recruiting”, without any explanation. Among 5 trials that were withdrawn, 3 listed “no funding” as an explanation, 1 listed “sponsor's decision and not a consequence of any safety concern”, and 1, led by Chinese scientist He Jiankui (ChiCTR1800019378), stated that “the original applicants cannot provide the IPD for reviewing.”

Only 3 trials from submitted and posted their results until May 2021 (Supplementary Table 2); results reporting times were 45.5, 31.8 and 28.0 months, respectively. All 3 trials, testing editing of CCR5 or PDCD1 gene in T cells, reported no deaths within 1 or 2 years. A single trial (NCT01543152) reported serious AEs (SAEs): staphylococcal cellulitis and substance abuse.

The median follow-up time for 21 trials without any results entry in and SCD until May 2021 was 17.3 months from the SCD (95% CI 6.2–32.6, range 2.2–100.0 months)

Characteristics of HGE technologies

The trials mostly tested the intervention in a single health condition (median 1, 95% CI 1.0–1.0, range 1–14), mostly cancers (70.4%) and HIV infection (14.8%) (Table 2).

Table 2 Characteristics of genome editing methodologies used in 81 trials registered in WHO ICTRP

Only 9 (11.1%) trials applied HGE tools directly to a participant’s organism, using nucleases for the treatment of HPV-related malignant neoplasm, hemophilia B, mucopolysaccharidosis, or different eye disorders.

We identified a trial on germline editing (ChiCTR1800019378) involving married Chinese couples with HIV seropositivity and fertility problems. The trial resulted in the birth of twin girls with CRISPR disabled CCR5 gene [28].

CRISPR/Cas9 was the most utilized genome editing platform (35.8%), followed by ZFN (21.0%, Table 2). Out of 33 trials that lacked registration data on the nuclease platform used, 21 (63.6%) were conducted in China.

The description of the delivery platform was absent for the majority of trials (80.2%). Half of trials that provided this information used adeno-associated virus vectors or mRNA (9.9%).

The development of chimeric antigen receptor (CAR) T cells was in the focus of 37 trials (45.7%); 27 of them (73.0%) studied allogeneic CAR T cells, 8 (21.6%) autologous, whilst for 2 trials (5.4%) CAR T cells origin was not precisely stated. B-lymphocyte antigen CD19 was the most commonly targeted protein among CAR therapies (n = 18, 48.6%, Table 3). Considering all included trials, knock-out of an immune checkpoint PD-1 was the sole aim for almost a fifth of trials (18.5%, Table 3).

Table 3 Registered targets in 81 clinical trials on genome editing in human participants from WHO ICTRP

Only 13 (16.0%) out of 81 trials explicitly stated the number of the ethics committee document or date of approval.

Comparison of registered and published data

Out of 81 trials, 12 trials (14.8%) in had results published in a journal (9 full-text and 3 progress reports).

For half of the trials, inclusion criteria were less informative in the publication than in the registry or were not specifically reported (Table 4). A sample size smaller than registered was reported in 5 out of 9 full-text reports. Participant’s age and sex matched in both sources for just over half of the trials.

Table 4 Comparison of selected protocol information registered and published for 12 trials on genome editing

The trials registered a median of 1 primary outcome measures (POMs) (95% CI 1–2, range 1–7) and 5.5 secondary (SOMs) (95% CI 2.0–10.6, range 1–21) in AEs were included in the registered POMs for all trials, except one (NCT03164135), which did not include AEs under any outcome measure. The number and description of SOMs matched in published full-text and for 2 out of 12 trials (Table 4).

A single trial, declared as a first-in-human phase 1 trial testing CRISPR/Cas9 PD-1-edited T cells in patients with advanced NSCLC (NCT02793856), had results both published and posted in The time frame of AE data collection matched in both sources. The total number of participants with grade 1/2 treatment-related AEs were congruently reported, but SAEs during follow-up were not reported in No death was reported in the registry data element “All-cause mortality”, but the article noted that 11 out of 12 participants died from tumor progression within 2 years.


Our study showed that registered trials using in vivo or ex vivo genome editing technology were mostly prospectively registered and recruiting phase 1 trials, focused mostly on immunotherapy that uses specially altered T cells, CAR T cell therapy, for different types of cancer. Trial results were underreported both in the registries and journal publications. All trials were related to somatic interventions, except a single one that resulted in a birth of two children. This trial involved major ethical violations and a call for international moratorium on the clinical use of human germline editing [29, 30].

In interpreting the findings, the following limitations should be addressed. The HGE Registry is a global registry recently created to track research on human genome editing [26] in the WHO ICTRP, which assembles the trial registration data sets provided by primary registries [31, 32]. However, taking into account that we identified additional 13 trials from two recently published overviews of trials on genome editing, there is a possibility that advanced search tools available at this moment in ICTRP are not sensitive and specific to identify all HGE trials. The number of trials we identified by combining the search of registries and published overviews is the highest among studies published to 2021 [5, 9, 11, 12]. As the trials on HGE were mostly in early phase 1 or phase 1 (51%), which are not subject to recently updated FDAAA registration and results reporting requirements [33], the sample may not be fully representative. We collected trial characteristics by assessing registration protocols that were not always complete.

The finding that only 14% of trials were completed could serve as another explanation for the poor results reporting rate identified in primary registries. It is important to point out that all trials whose status was noted as completed were from, the registry with a structured database for results dissemination. Of these completed trials, phase 1 was reported for 64%. However, our findings are consistent with similar studies showing that reporting of results has not yet become routine in research practice [34, 35], especially for trials at earlier stages [36, 37]. Anderson et al. showed that only 13% of 13,327 analyzed trials reported summary results within 1 year after completion [37]. Still, it is difficult to interpret the rate of results reporting for trials involving technologies that are incomparable to conventional drugs, and for which regulatory requirements are still not fully established. In line with that, regulatory reforms for phase 1 trials should be considered in order to optimize the benefits and lessen potential harms from trials including HGE. Among the only 3 completed trials with results registered until May 2021, we showed that none has reported deaths and only one reported SAEs. The AEs underreporting in GT trials was already an issue in 2000 after the first publicly identified death of trial participant [16], when NIH announced that only 39 out of 691 GT-related SAEs in the last 7 years had been reported promptly, as required [38]. Despite 14% trials having completed status, a total of 33 trials (41%) reported SCD before May 2021. Among them, 21 trials (64%) were from and remained without submitted results within the median follow-up time of 1.4 years after the SCD. The number of withdrawn, terminated, or trials of unknown status, and identified discrepancies in recruitment status and SCD, all point to challenges in ensuring high quality of data in public registries in general, and for HGE trials in particular. This is in line with the common inadequate updating of registered data [39, 40] even after more than 15 years of the implementation of trial registration [32] and more than 13 years of the legal mandate for results registration [22]. However, the prospective registration rate of almost 70% among HGE trials is higher than the reported 42% prospective registration rate from a 2018 study of 10,500 RCTs published in 2105 journals [41]. Prospective protocol registration is especially important for HGE trials since an expert assessment of publicly available information might prevent unethical, unsafe, illegal, or research without proper scientific justification to be conducted [42].

The discrepancies between the registry and corresponding publications regarding protocol and safety data are another issue of concern. It should be noted that the publication rate of 15% correlates with the percentage of trials with completed status reported under the recruitment information registration field. In a single trial that had both registered and published results, we identified absent reporting of SAEs and all-cause mortality in Moreover, in comparison to registered data, eligibility criteria were mostly underreported in publications. Since incomplete reporting of trial data is often credited to space restrictions in journals [43], the peer-review process may play a more important role in augmenting trial transparency. Nonetheless, it is important to keep in mind that 58% trials had SCD after May 2021, and that a full-text article was identified for only 9 trials at the moment of publication search.

Almost half of the included trials investigated applications of CAR T cells in human subjects. The fast evolution of CAR T cell therapies in both number and type [44] guided the recent inclusion of an annex on CAR T cells in EMA’s guidance on the development of new medicinal products for human use containing genetically modified cells [45]. Universal CAR T cells for specific antigens of interest were generated from allogeneic T cells from healthy donors in more than 70% of the previously mentioned trials. However, these “off-the-shelf” products for large-scale clinical applications are still at their infancy, waiting for the establishment of clinical, industrial, and regulatory standards [46].

Our study showed that CRISPR technology were used more often than ZFNs and TALENs, which could be partially attributed to the difficulty in cloning and protein engineering for ZNF and TALEN, and their less simple and flexible use [12, 47]. The CRISPR technique can be readily and affordably adapted to simultaneously target genome sequence at multiple sites, with remarkable efficiency [48]. Despite that, the potential immunogenicity to CRISPR-Cas9 proteins could be a potential limitation for the use in humans [49], and should be monitored in HGE trials.

It is difficult to discuss the vector systems used for HGE since 80% trials did not register this information. However, among trials with delivery platform recorded, viral vectors were among the most commonly used, probably because they lack the propensity to integrate or reactivate following latency and thus carry a lower risk of delayed AEs [19].

Regarding trial design, the majority of identified ICTRP trials were early-phase trials, initially evaluating safety, tolerability, or feasibility of administration of investigational products [1]. RCTs are generally recommended, according to the EMA’s guidance related to clinical aspects of GT products from 2018, but with acceptable alternatives if appropriately justified [2]. Early-phase design for GT products is more complex than for other product types, as stated in FDA’s guidance released in 2015, and a case-by-case estimation is recommended in the trial planning [1].

Keeping in mind that the use of blinding and the control group in phase 1 or 2 are generally not as crucial as for confirmatory efficacy trial [1], only 4 out of 78 identified interventional HGE trials were blinded. The placebo comparator group was used in 3 trials focused on cancer immunotherapy and included an invasive procedure for the collection of patient’s T lymphocytes. Despite the fact that such a control could help differentiate product-related from procedure-related effects and be relevant for phase 3 trial as well, the use of the invasive procedure in the control group may be an important risk [1].

The finding that more than 80% of trials registered in WHO ICTRP clearly reported non-inclusion of healthy subjects is in line with the recently mentioned FDA’s recommendations [1], regarding unacceptable benefit-risk ratio in most trials with GT products.

The minimal age of participants included in the trials was below 11 years for 15% trials, whilst 56% trials included patients 65 years of age and older. Since specific effects of HGE could be different in children, adults or the elderly, such as the immunogenicity of a viral vector, taking vulnerable populations into consideration during GT development is encouraged in both EMA’s [2] and FDA’s guidance [1].

It is important to point out that pre-market trials of reasonable duration and sample size cannot fully predict the durability of response and the risk for delayed AEs, which makes the clinical review of HGE products more challenging in comparison with conventional drugs [4]. In our study, 3 LTFU studies were identified, but only 1 specified the duration of the extension study, where enrolled subjects will be evaluated for a total of 12 years (NCT04201782). This is in line with recommended “up to fifteen years for genome editing products” in current FDA guidance on LTFU after administration of human GT products [19], and recently updated EMA guidance [45].

Only 20% of analyzed trials were willing to provide an access to IPD and enable the re-use of data. Public posting of informed consent form (ICF) in the trial registry is still not required by the 24-item WHO TRDS, but it might help safeguard subjects from unethical behavior that in the past HGE trials resulted in death or SAEs [50]. In this context, we propose to broaden current WHO registration data elements specifically for HGE trials by including ICF, as well as expanded access information, which should follow the appropriate FDA regulations (21 CFR 312) [51]. Despite the value of data collected during the compassionate use of conventional drugs is mostly considered as limited [52], non-trial preapproval use might provide important information on outcomes and AEs related to this unique class of therapeutics, mostly intended for patient populations that may be small, and whose effects in most cases cannot be reversed [53]. Other steps required to improve the transparency of HGE trials are more demanding, since the WHO ICTRP platform gathers trial registration data sets provided by different primary registries, still not completely complying with the WHO TRDS [54]. However, in 2021 WHO launched recommendations on the governance of HGE on a global scale, including also their trial registration, for which the “traditional” international standards should be particularly adapted [42]. Special emphasis should be put on having the appropriate ethics approval before the inclusion in the WHO HGE Registry. Furthermore, a small expert committee should be established, whose role would be to regularly screen the Registry and assess the compliance of planned and ongoing HGE trials, using a unique registration data set, yet to be standardized [42]. Governments, relevant healthcare and scientific organizations, ethic committees, funders, researchers, journal editors, and reviewers, should put exceptional efforts to enable these potentially life-saving technologies to be responsibly integrated into clinical practice.


To support safe innovation in this field, product developers should be provided with more specific regulatory guidance reflecting accumulating clinical experience and referring explicitly to HGE products; their development, manufacture, product approval, and follow-up, as well as registration technical requirements. High quality, informative and timely registration of trial protocol and results should be a prerequisite in the clinical regulatory procedure, and the international HGE Registry provided by WHO is a critical and necessary first step toward increasing the transparency of trials on human genome editing, with many fields for advance.

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.



Adverse event


Chimeric antigen receptor


CRISPR-associated protein 9


Chemokine receptor 5


The Code of Federal Regulations


Clustered regularly interspaced short palindromic repeats


European Medicines Agency


Food and Drug Administration


Food and Drug Administration Amendments Act


Gene therapy


Human genome editing


Informed consent form


Individual participant data


Long-term follow-up

NCT number:

National Clinical Trial number


National Institutes of Health


Non-small cell lung cancer


Primary completion date


Programmed cell death protein 1


Programmed cell death protein 1


Primary outcome measure


Randomized controlled trial


Serious adverse event


Study completion date


Secondary outcome measure


Transcription activator-like effector nuclease


Allogeneic engineered T-cells expressing anti-CD19 chimeric antigen receptor


World Health Organization International Clinical Trial Registry Platform


World Health Organization Trial Registration Data Set


Zinc finger nuclease


  1. US Food and Drug Administration. Considerations for the design of early-phase clinical trials of cellular and gene therapy products. 2015. Accessed 30 June 2021.

  2. European Medicines Agency. Guideline on the quality, non-clinical and clinical aspects of gene therapy medicinal products. 2018. Accessed 30 June 2021.

  3. US Food and Drug Administration. Chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs). 2020. Accessed 30 June 2021.

  4. US Food and Drug Administration. FDA continues strong support of innovation in development of gene therapy products. 2020. Accessed 3 Mar 2021.

  5. Ernst MPT, Broeders M, Herrero-Hernandez P, Oussoren E, van der Ploeg AT, Pijnappel W. Ready for repair? Gene editing enters the clinic for the treatment of human disease. Mol Ther Methods Clin Dev. 2020;18:532–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Broeders M, Herrero-Hernandez P, Ernst MPT, van der Ploeg AT, Pijnappel W. Sharpening the molecular scissors: advances in gene-editing technology. iScience. 2020;23(1):100789.

    Article  CAS  PubMed  Google Scholar 

  7. Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013;31(7):397–405.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. National Academies of Sciences, Engineering, and Medicine. 2017. Human Genome Editing: Science, Ethics, and Governance. The National Academies Press. Washington, DC.

  9. Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther. 2020;5(1):1.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Carroll D. Genome editing: past, present, and future. Yale J Biol Med. 2017;90(4):653–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  11. Cornu TI, Mussolino C, Cathomen T. Refining strategies to translate genome editing to the clinic. Nat Med. 2017;23(4):415–23.

    Article  CAS  PubMed  Google Scholar 

  12. Ghosh D, Venkataramani P, Nandi S, Bhattacharjee S. CRISPR-Cas9 a boon or bane: the bumpy road ahead to cancer therapeutics. Cancer Cell Int. 2019;19:12.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Bulaklak K, Gersbach CA. The once and future gene therapy. Nat Commun. 2020;11(1):5820.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Boardman F. Human genome editing and the identity politics of genetic disability. J Community Genet. 2020;11(2):125–7.

    Article  PubMed  Google Scholar 

  15. Doudna JA. The promise and challenge of therapeutic genome editing. Nature. 2020;578(7794):229–36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Raper SE, Chirmule N, Lee FS, Wivel NA, Bagg A, Gao GP, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab. 2003;80(1–2):148–58.

    Article  CAS  PubMed  Google Scholar 

  17. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, et al. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302(5644):415–9.

    Article  CAS  PubMed  Google Scholar 

  18. Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot L, et al. Donor-derived brain tumor following neural stem cell transplantation in an ataxia telangiectasia patient. PLoS Med. 2009;6(2):e1000029.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. US Food and Drug Administration. Long term follow-up after administration of human gene therapy products. 2020. Accessed 30 June 2021.

  20. European Medicines Agency. Guideline on follow-up of patients administered with gene therapy medicinal products. 2009. Accessed 30 June 2021.

  21. Tse T, Williams RJ, Zarin DA. Reporting “basic results” in Chest. 2009;136(1):295–303.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Food and Drug Administration Amendments Act of 2007. 21 U.S.C. Public Law 110–85 2007: Sect. 801. Accessed 30 June 2021.

  23. Schwartz LM, Woloshin S, Zheng E, Tse T, Zarin DA. and Drugs@FDA: a comparison of results reporting for new drug approval trials. Ann Intern Med. 2016;165(6):421–30.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Shepshelovich D, Goldvaser H, Wang L, AbdulRazak AR, Bedard PL. Comparison of reporting phase I trial results in and matched publications. Invest New Drug. 2017;35(6):827–33.

    Article  CAS  Google Scholar 

  25. Tang E, Ravaud P, Riveros C, Perrodeau E, Dechartres A. Comparison of serious adverse events posted at and published in corresponding journal articles. BMC Med. 2015;13:189.

    Article  PubMed  PubMed Central  Google Scholar 

  26. World Health Organization. Human Genome Editing (HGE) Registry. Accessed 30 June 2021.

  27. World Health Organization. WHO Trial Registration Data Set (Version 1.3.1). 2017. Accessed 30 June 2021.

  28. Regalado A. China’s CRISPR babies: Read exclusive excerpts from the unseen original research. MIT Technology Review. 2019. Accessed 30 June 2021.

  29. Lander ES, Baylis F, Zhang F, Charpentier E, Berg P, Bourgain C, et al. Adopt a moratorium on heritable genome editing. Nature. 2019;567(7747):165–8.

    Article  CAS  PubMed  Google Scholar 

  30. Wolinetz CD, Collins FS. NIH supports call for moratorium on clinical uses of germline gene editing. Nature. 2019;567(7747):175.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Laine C, Horton R, DeAngelis CD, Drazen JM, Frizelle FA, Godlee F, et al. Clinical trial registration: looking back and moving ahead. Lancet. 2007;369(9577):1909–11.

    Article  PubMed  Google Scholar 

  32. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al. Clinical trial registration: a statement from the International Committee of Medical Journal Editors. Lancet. 2004;364(9438):911–2.

    Article  PubMed  Google Scholar 

  33. Final Rule: clinical trials registration and results information submission. Fed Regist 2016;81:64981e5157.

  34. Wise J. Clinical trial reporting: compliance with US rules is poor and not improving, study finds. BMJ. 2020;368:m217.

    Article  PubMed  Google Scholar 

  35. DeVito NJ, Goldacre B. Evaluation of compliance with legal requirements under the FDA Amendments Act of 2007 for timely registration of clinical trials, data verification, delayed reporting, and trial document submission. JAMA Intern Med. 2021;181(8):1128–30.

    Article  PubMed  Google Scholar 

  36. Saito H, Gill CJ. How frequently do the results from completed US clinical trials enter the public domain? A statistical analysis of the database. PLoS One. 2014;9(7):e101826. eCollection 2014.

  37. Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at N Engl J Med. 2015;372(11):1031–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Wadman M. NIH under fire over gene-therapy trials. Nature. 2000;403(6767):237.

    Article  CAS  PubMed  Google Scholar 

  39. Jones CW, Safferman MR, Adams AC, Platts-Mills TF. Discrepancies between recruitment status and actual trial status: a cross-sectional analysis. BMJ Open. 2017;7(10):e017719.

    Article  PubMed  PubMed Central  Google Scholar 

  40. Fleminger J, Goldacre B. Prevalence of clinical trial status discrepancies: a cross-sectional study of 10,492 trials registered on both and the European Union Clinical Trials Register. PLoS One. 2018;13(3):e0193088.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Al-Durra M, Nolan RP, Seto E, Cafazzo JA. Prospective registration and reporting of trial number in randomised clinical trials: global cross sectional study of the adoption of ICMJE and Declaration of Helsinki recommendations. BMJ. 2020;369:m982.

    Article  PubMed  PubMed Central  Google Scholar 

  42. World Health Organization Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing. Human genome editing: recommendations. 2021. Accessed 17 Feb 2022.

  43. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet. 2009;374(9683):86–9.

    Article  PubMed  Google Scholar 

  44. MacKay M, Afshinnekoo E, Rub J, Hassan C, Khunte M, Baskaran N, et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat Biotechnol. 2020;38(2):233–44.

    Article  CAS  PubMed  Google Scholar 

  45. European Medicines Agency. Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells. 2020. Accessed 30 June 2021.

  46. Zhao J, Lin Q, Song Y, Liu D. Universal CARs, universal T cells, and universal CAR T cells. J Hematol Oncol. 2018;11(1):132.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Adli M. The CRISPR tool kit for genome editing and beyond. Nat Commun. 2018;9(1):1911.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Hampton T. With first CRISPR trials, gene editing moves toward the clinic. JAMA. 2020;323(16):1537–9.

    Article  PubMed  Google Scholar 

  49. Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK, et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019;25(2):249–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Sibbald B. Death but one unintended consequence of gene-therapy trial. CMAJ. 2001;164(11):1612.

    CAS  PubMed  PubMed Central  Google Scholar 

  51. US Food and Drug Administration. CFR - Code of Federal Regulations Title 21, Volume 5. Part 312 - Investigational New Drug Application. Subpart I - Expanded Access to Investigational Drugs for Treatment Use. Accessed 17 Feb 2022.

  52. Borysowski J, Ehni HJ, Gorski A. Ethics review in compassionate use. BMC Med. 2017;15(1):136.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Kearns L, Chapman CR, Moch KI, Caplan AL, Watson T, McFadyen A, et al. Gene therapy companies have an ethical obligation to develop expanded access policies. Mol Ther. 2021;29(4):1367–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Moja LP, Moschetti I, Nurbhai M, Compagnoni A, Liberati A, Grimshaw JM, et al. Compliance of clinical trial registries with the World Health Organization minimum data set: a survey. Trials. 2009;10:56.

    Article  PubMed  PubMed Central  Google Scholar 

Download references


Not applicable.


This study was funded by the Croatian Science Foundation (“Professionalism in Health—Decision making in practice and research, ProDeM”) under Grant agreement No. IP-2019–04-4882. The funder had no role in the design of the study; the collection, analysis, and interpretation of the data; and the decision to approve publication of the finished manuscript.

Author information

Authors and Affiliations



All authors (DJ, MZ, AM) generated the idea, designed the study, and selected the trials. DJ and MZ extracted data after all authors consent to the selection of trials and final extraction protocol. All authors interpreted and analyzed the data. DJ and MZ drafted the article, while AM critically revised it for important intellectual content. All authors approved the submitted version. All authors agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Corresponding author

Correspondence to Diana Jurić.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Additional file 1:

Supplementary Table 1. Characteristics of participants included in 81 trials using HGE technologies and registered in WHO ICTRP. Supplementary Table 2. Characteristics of conduct of 81 trials using HGE technologies and registered in WHO ICTRP.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jurić, D., Zlatin, M. & Marušić, A. Inadequate reporting quality of registered genome editing trials: an observational study. BMC Med Res Methodol 22, 131 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: